Mouse models for dengue vaccines and antivirals.
Dengue virus (DENV) has substantial global impact, with an estimated 390million people infected each year. In spite of this, there is currently no approved DENV-specific vaccine or antiviral. One reason for this is the difficulty involved with development of an adequate animal model. While non-human primates support viral replication, they do not exhibit signs of clinical disease. A mouse model is an ideal alternative; however, wild-type mice are resistant to DENV-induced disease. Infection of interferon receptor-deficient mice results in disease that recapitulates key features of severe dengue disease in humans. For the development of vaccines, interferon receptor-deficient mice provide a stringent model for testing vaccine-induced immune components from vaccinated wild-type mice.
La Jolla Institute for Allergy and Immunology, La Jolla, CA, USA.
Emily M
EM
Plummer
La Jolla Institute for Allergy and Immunology, La Jolla, CA, USA. Electronic address: sujan@lji.org.
Sujan
S
Shresta
D000818:Animals; D003715:Dengue / Q000235:genetics / Q000276:immunology* / Q000517:prevention & control*; D053059:Dengue Vaccines / Q000235:genetics / Q000276:immunology*; D003716:Dengue Virus / Q000502:physiology*; D004195:Disease Models, Animal; D006801:Humans; D007371:Interferon-gamma / Q000235:genetics / Q000276:immunology; D051379:Mice; D008817:Mice, Mutant Strains; D014779:Virus Replication / Q000235:genetics / Q000276:immunology*
D053059:Dengue Vaccines; D007371:Interferon-gamma
Dengue virus; Mouse model; Non-human primate